Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities

Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities

HM-3, an integrin antagonist, exhibits anti-tumor biological responses and therefore has potential as a therapeutic polypeptide. However, the clinical applications of HM-3 are limited by its short half-life. In this study, we genetically fused human serum albumin (HSA) to the N or C-terminus of HM-3...

Full description

Bibliographic Details
Main Authors: Ting Li, Han-Zi Zhang, Guang-Fei Ge, Zhao-Rong Yue, Ru-Yue Wang, Qian Zhang, Yan Gu, Mei-Juan Song, Wen-Bo Li, Min-Zhi Ma, Mei-Zhu Wang, Hui Yang, Yang Li, Hong-Yu Li
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Biomedicines
Subjects:
fusion protein
expression
anti-tumor
half-life
Online Access:https://www.mdpi.com/2227-9059/9/9/1084

Internet

https://www.mdpi.com/2227-9059/9/9/1084

Similar Items